Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment

Bhavna H. Chohan, Keshet Ronen, Brian Khasimwa, Lusi Osborn, Jennifer A. Unger, Alison L. Drake, Ingrid A. Beck, Lisa M. Frenkel, John Kinuthia, Grace John-Stewart

1 Department of Global Health, University of Washington, Seattle, Washington, United States of America, 2 Center for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya, 3 Department of Pediatrics, University of Nairobi, Nairobi, Kenya, 4 Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya, 5 Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America, 6 Center for Infectious Diseases Research, Seattle Children's Research Institute, Seattle, Washington, United States of America, 7 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 8 Department of Pediatrics, University of Washington, Seattle, Washington, United States of America, 9 Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America, 10 Department of Epidemiology, University of Washington, Seattle, Washington, United States of America

☯ These authors contributed equally to this work.
† Deceased.
* bchohan@u.washington.edu

Abstract

We determined social and behavioral factors associated with virologic non-suppression among pregnant women receiving Option B+ antiretroviral treatment (ART). Baseline data was used from women in Mobile WACHX trial from 6 public maternal child health (MCH) clinics in Kenya. Virologic non-suppression was defined as HIV viral load (VL) ≥ 1000 copies/ml. Antiretroviral resistance testing was performed using oligonucleotide ligation (OLA) assay. ART adherence information, motivation and behavioral skills were assessed using LifeWings IMB tool, depression using PHQ-9, and food insecurity with the Household Food Insecurity Access Scale. Correlates of virologic non-suppression were assessed using Poisson regression. Among 470 pregnant women on ART ≥ 4 months, 57 (12.1%) had virologic non-suppression, of whom 65% had HIV drug resistance mutations. In univariate analyses, risk of virologic non-suppression was associated with moderate-to-severe food insecurity (RR 1.80 [95% CI 1.06–3.05]), and varied significantly by clinic site (range 2%-22%, p < 0.001). In contrast, disclosure (RR 0.36 [95% CI 0.17–0.78]) and having higher adherence skills (RR 0.70 [95% CI 0.58–0.85]) were associated with lower risk of virologic non-suppression. In multivariate analysis adjusting for clinic site, disclosure, depression symptoms, adherence behavior skills and food insecurity, disclosure and food insecurity remained associated with virologic non-suppression. Age, side-effects, social support, physical or emotional abuse, and distance were not associated with virologic non-suppression. Prevalence of virologic non-suppression among pregnant women on ART was appreciable and associated with food insecurity.
insecurity, disclosure and frequent drug resistance. HIV VL and resistance monitoring, and tailored counseling addressing food security and disclosure, may improve virologic suppression in pregnancy.

Introduction

Prevention of mother-to-child HIV transmission (PMTCT) programs currently reach >90% of pregnant women in regions of sub-Saharan Africa (SSA) [1]. While high antiretroviral treatment (ART) coverage is encouraging, poor ART adherence in pregnancy and postpartum remains a challenge. Poor ART adherence in pregnancy can lead to viral non-suppression and HIV drug resistance, increasing risk of maternal treatment failure and MTCT [2, 3]. Prevalence of drug resistance among pregnant or postpartum women living with HIV (WLWH) in SSA has ranged from 6% to 46% [4–7].

Adherence to ART may falter during pregnancy or postpartum due to varied factors, including stigma, non-disclosure, partner violence, and side-effects [2, 8–12]. Food insecurity has been associated with virologic non-suppression in adults and with maternal stress in the peripartum period [13–17]. It is also important to understand women’s motivation, knowledge, and behavioral skills to sustain ART adherence in pregnancy.

Materials and methods

Study population

This post-hoc analysis used enrollment data from a 3-arm randomized controlled trial (RCT) of short message service (SMS) in PMTCT (Mobile WACHX, NCT02400671), conducted at 6 public, Ministry of Health MCH clinics in Kenya. Women were eligible if they were ≥14 years old, attending antenatal care (ANC), HIV-infected, and had daily access to a mobile phone. The design and methods of the Mobile WACHX study have been described [18]. In brief, pregnant WLWH were enrolled between November 2015 and May 2017, and randomized to 1-way SMS, 2-way SMS, or control (no SMS). A questionnaire was administered to ascertain ART adherence information, motivation and behavioral skills (IMB) using an abbreviated LifeWindows instrument [19], social support using the Medical Outcomes Study (MOS) survey [20], partner abuse using the Abuse Assessment Screen [21], and depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9) [22]. Stigma was assessed using the 4-question version of the Stigma Scale for Chronic Illness (SSCI) [23]. Food security was assessed using the Household Food Insecurity Access Scale (HFIAS) [16, 24]. ART initiation date and regimen were abstracted from clinic records. Participant blood samples were collected to perform ARV resistance analyses and HIV VL test if required. A survey was conducted to assess facility PMTCT services to examine if any services or clinic characteristics were associated with virologic non-suppression among the women. Follow-up of Mobile WACHX participants lasted 24 months, with the final study visit conducted in January 2020. This manuscript presents analysis of enrollment data only.

Virologic analyses. At enrolment, consent was obtained and participant VL was abstracted from program data. If program VL was unavailable, VL testing of study samples was conducted at the Kenya Medical Research Institute (KEMRI)/Centers for Disease Control and Prevention (CDC) in Kisumu or Nairobi, Kenya using the Roche COBAS® TaqMan® Analyzer or COBAS® TaqMan® Version 2.0 (CAP/CTMv2.0) platform with a lower limit of quantification of 40 copies/ml.
ARV resistance analyses. ARV drug resistance mutations were identified in cryopreserved plasma samples from women with HIV RNA levels ≥ 1000 copies/mL using an oligonucleotide ligation assay (OLA) [25]. The OLA assay detects mutations at HIV-1 pol reverse transcriptase codons 65, 103, 181, 184, and 190 that can confer resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and nucleoside/tide reverse transcriptase inhibitors (NRTI). OLA probes have been optimized for HIV subtypes A, D, and C, common in Kenya [25]. Viral RNA extracted from plasma was reverse-transcribed and resultant cDNA was analyzed using OLA and consensus sequencing when OLA testing failed at any of the codons analyzed [25]. The study classified resistance mutations as detected if they were at an abundance of 10% or more.

Statistical methods and data analysis. Statistical analysis was performed using Stata version 13 [26]. PHQ-9 scores were dichotomized with score ≥ 5 indicating at least mild depressive symptoms. HFIAS scores classified food insecurity into four levels per instrument guidelines: food secure, mildly, moderately, or severely food insecure and dichotomized into secure/mildly insecure vs. moderate/severely insecure [24]. Virologic non-suppression was defined as VL ≥ 1000 copies/mL. Analysis was restricted to women on ART for ≥ 4 months at enrollment, to allow sufficient time to achieve virologic suppression. Correlates of virologic non-suppression were determined by Poisson regression with robust standard errors. Multivariate analysis was conducted including all variables that were associated with virologic non-suppression in univariate analysis at a significance level of p < 0.1.

Ethical review. Ethical approval was obtained from the University of Washington and Kenyatta National Hospital/University of Nairobi institutional review boards. The study was performed in accordance with ethical standards in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Participants provided written informed consent prior to enrollment.

Results
Study population
Among 824 participants, 470 women had been on ART for ≥ 4 months at enrollment and were included in analyses. Median age was 28 years, the majority (86.0%) of women were married or cohabiting, and 9.2% were primigravida. Overall, 122 (26.0%) women reported at least mild depressive symptoms (PHQ9 score ≥ 5). There was a high rate of HIV status disclosure with 96.6% women reporting disclosure to anyone and 90.1% reporting disclosure to their partner. The majority (61.9%) of women were on efavirenz-based ART. Of the 470 women included in the analysis, 429 (91.3%) VL results were evaluated by the study from study plasma specimens, while 41 (8.7%) were obtained from clinical record abstraction. Of these 470 women, 57 (12.1%) women had unsuppressed viral load (VL ≥ 1000 copies/ml).

HIV drug resistance in women with non-suppressed VL
Among 57 women with virologic non-suppression, 54 were tested for resistance. Thirty-five (64.8%) had detectable mutations conferring resistance to NNRTIs and NRTIs (S1 Fig), of whom 32 were on NNRTIs (15 on TDF/3TC/EFV, 9 on TDF/3TC/NVP, 8 on ZDV/3TC/NVP), and 3 were on PI-based ART (TDF/3TC/LPV/r or ZDV/3TC/LPV/r or ZDV/3TC/ATV/r).

Among women on NNRTI-based ART, single resistance mutations detected were: K103N only (n = 5), Y181C only (n = 2), G190A only (n = 2), M184V only (n = 1); dual mutations: K103N and M184V (n = 11), G190A and M184V (n = 3), Y81C and M184V (n = 2); and multiple mutations: K103N, G190A and M184V (n = 2); Y181C, G190A and M184V (n = 1);
Y181C, K65R and M184V (n = 3); K103N + K65R + M184V (n = 1); G190A + K65R + M184V (n = 1); and G190A + K101H + M184V (n = 1) (S1 Fig). We detected G190A, a NNRTI mutation in 2 women on LPV/r-based ART, and a K103N mutation in one woman on ATV/r-based ART, suggesting either transmitted drug resistance or prior exposure to NNRTI-based ARVs among 3 women on PI-based ART.

Correlates of virologic non-suppression

HIV status disclosure was associated with lower risk of virologic non-suppression: 11.3% women who had disclosed were unsuppressed compared with 31.3% of those who had not disclosed (RR 0.36 [95% CI 0.17–0.78]) (Table 1). Higher IMB scores were associated with lower risk of virologic non-suppression (RR 0.67 [95% CI 0.46–0.98] per 10% increase in IMB score). In analyses of IMB components, only behavior skills were associated with lower risk of non-suppression (RR 0.70 [95% CI 0.58–0.85]). Moderate-to-severe food insecurity was also associated with virologic non-suppression: 15.2% of food-insecure women had unsuppressed VL compared with 8.5% of food-secure women (RR 1.80 [95% CI 1.06–3.05]). Marital status, self-reported ART adherence, history of side effects, social support, history of partner abuse or distance from home to clinic were not associated with virologic non-suppression. In multivariate analysis adjusted for all variables associated with virologic non-suppression in univariate analysis, virologic non-suppression remained significantly associated with food insecurity (aRR 2.07 [95% CI 1.15–3.72]) and status disclosure (aRR 0.34 [95% CI 0.15–0.78]) (Table 1). Differences by clinic also remained statistically significant.

Prevalence of virologic non-suppression was significantly higher at 2 clinics (one in Nairobi, 22%; one in Western Kenya, 25%), compared with other clinics (prevalence 2–11%) (Table 1). We did not detect significant differences between facilities in staffing levels, experience dispensing ART, ART stockouts, practices regarding VL testing, or support provided to patients with non-suppression (S1 Table). There was a higher prevalence of depression (p < 0.001) and lower median IMB scores (p < 0.001) among study participants in facilities with a higher prevalence of virologic non-suppression (20%) (S2 Table).

Discussion

In this study of pregnant women on ART for ≥ 4 months attending urban and rural clinics in Kenya, 12% had unsuppressed HIV VL, 65% of whom had resistance mutations. Women who had not disclosed their HIV status, had food insecurity, and had poorer adherence behavioral skills were more likely to have virologic non-suppression. In multivariate analysis, status disclosure and food insecurity were independently associated with virologic non-suppression. Prevalence of virologic non-suppression varied by clinic; however, there were no discernable facility characteristics associated with non-suppression.

Our findings are consistent with other studies from SSA, which report 6–20% prevalence of virologic non-suppression among women on Option B+ [6, 27–30]. However, most of these studies evaluated VL postpartum following ART initiation in pregnancy, in contrast to our study which focused on pregnancy. The majority of women entering PMTCT programs in SSA are already on ART [31]. Our study suggests that assessing VL among pregnant women already on ART remains important.

Among women with unsuppressed VL in our study, 65% had detectable resistance mutations, mainly to NNRTIs. Rates of drug resistance among women on Option B+ in SSA have ranged from 6% to 46% in smaller studies [4, 5]. Our findings suggest a need for resistance testing among pregnant women receiving NNRTI regimens. With increased use of dolutegravir, rates of resistance are expected to decrease [32, 33].
|                          | Suppressed VL (<1000 c/ml) | Unsuppressed VL (≥1000 c/ml) | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------------|-----------------------------|---------------------|-----------------------|
|                          | n(%) or median (IQR)      |                             | RR (95% CI)         | p-value               |
| Overall                  | 413 (87.9%)               | 57 (12.1%)                  | 0.98 (0.95–1.03)    | 0.47                  |
| Age (years)              | 28 (24–32)                | 28 (25–31)                  | 1.00 (0.97–1.03)    | 0.98                  |
| Marital status           |                           |                             | 0.61 (0.34–1.10)    | 0.10                  |
| Married/cohabiting       | 359 (88.9)                | 45 (11.1)                   | 1.54 (0.87–2.71)    | 0.14                  |
| Unmarried & not cohabiting | 54 (81.8)               | 12 (18.2)                   | 0.98 (0.58–1.65)    | 0.94                  |
| Self-reported adherence on VAS |                   |                             | 1.12 (0.57–2.18)    | 0.74                  |
| <95% on VAS              | 74 (84.1)                 | 14 (15.9)                   | 0.70 (0.58–0.85)    | <0.001                |
| ≥95% on VAS              | 338 (89.7)                | 39 (10.3)                   | 0.97 (0.80–1.17)    | 0.48                  |
| ART doses missed in last 30 days |                   |                             | 0.80 (0.44–1.45)    | 0.47                  |
| >0                       | 50 (90.9)                 | 5 (9.1)                     | 0.70 (0.58–0.85)    | <0.001                |
| 0                        | 352 (88.4)                | 46 (11.6)                   | 0.70 (0.58–0.85)    | <0.001                |
| History of regimen switch |                           |                             | 1.54 (0.60–3.94)    | 0.37                  |
| Yes                      | 211 (84.0)                | 4 (16.0)                    | 1.54 (0.93–2.55)    | 0.09                  |
| No                       | 122 (89.6)                | 13 (10.4)                   | 1.12 (0.57–2.18)    | 0.74                  |
| Any side effects in last 30 days |                   |                             | 1.04 (0.93–1.17)    | 0.51                  |
| Yes                      | 121 (90.3)                | 13 (9.7)                    | 1.80 (1.06–3.05)    | 0.03                  |
| No                       | 291 (87.9)                | 40 (12.1)                   | 2.07 (1.15–3.72)    | 0.02                  |
| ART adherence IMB %*     | 77.3 (73.3–82.7)          | 76.7 (70.0–82.0)            | 0.67 (0.46–0.98)    | 0.04                  |
| Information score %*     | 85.0 (80.0–95.0)          | 85.0 (75.0–100.0)           | 0.96 (0.78–1.17)    | 0.66                  |
| Motivation score %*      | 55.0 (40.0–75.0)          | 60.0 (40.0–75.0)            | 1.01 (0.89–1.15)    | 0.88                  |
| Behavior skills score %* | 82.9 (77.1–91.4)          | 80.0 (74.3–85.7)            | 0.70 (0.58–0.85)    | <0.001                |
| Depression symptoms      |                           |                             | 1.54 (0.93–2.55)    | 0.09                  |
| ≥mild (≥5 PHQ9)          | 102 (83.6)                | 20 (16.4)                   | 1.12 (0.57–2.18)    | 0.74                  |
| <mild (<5 PHQ9)          | 311 (89.4)                | 37 (10.6)                   | 1.04 (0.93–1.17)    | 0.51                  |
| Social support score %*  | 88.9 (69.4–100.0)         | 87.5 (75.0–100.0)           | 1.80 (1.06–3.05)    | 0.03                  |
| Food security            |                           |                             | 2.07 (1.15–3.72)    | 0.02                  |
| Moderate/severe food insecurity | 218 (84.8)             | 39 (15.2)                   | 0.90 (0.57–1.40)    | 0.51                  |
| ≤Mild food insecurity    | 195 (91.6)                | 18 (8.5)                    | 0.70 (0.47–1.05)    | 0.13                  |
| Time to travel to clinic (minutes) | 30.0 (20.0–60.0)     | 30.0 (22.5–60.0)            | 1.00 (0.99–1.01)    | 0.45                  |
| Status disclosure to partner |                     |                             | 0.60 (0.30–1.20)    | 0.15                  |
| Yes                      | 357 (89.0)                | 44 (11.0)                   | 0.36 (0.17–0.78)    | 0.01                  |
| No                       | 36 (81.8)                 | 8 (18.2)                    | 0.34 (0.15–0.78)    | 0.01                  |
| Status disclosure to anyone |                     |                             | 0.36 (0.17–0.78)    | 0.01                  |
| Yes                      | 401 (88.7)                | 51 (11.3)                   | 0.34 (0.15–0.78)    | 0.01                  |
| No                       | 11 (68.8)                 | 5 (31.3)                    | 0.34 (0.15–0.78)    | 0.01                  |

(Continued)
We used the LifeWindows IMB ART Adherence Questionnaire, which evaluates domains that influence ART adherence based on the IMB behavioral theory—information, motivation and behavioral skills [34, 35]. Women with lower scores were more likely to have virologic non-suppression and this association was driven by differences in behavior skills rather than motivation or information. To our knowledge, this is the first evaluation of the IMB construct in PMTCT programs. Rapid assessment of behavioral skills using this instrument could be used to identify clients who need support. Although this association was not independently significant when adjusting for other correlates, univariate association of this easily assessed construct is potentially clinically meaningful and actionable.

Women in our study who had disclosed their HIV status were less likely to have virologic non-suppression, consistent with other studies [36]. Women with virologic non-suppression had higher prevalence of moderate or severe household food insecurity, consistent with studies in other populations [13–15, 37]. To our knowledge, this is the first study assessing food insecurity and virologic non-suppression in PMTCT and suggests that food supplementation or agricultural support may optimize both maternal-child nutrition and viral suppression. Our findings suggest that wholistic care that addresses depression, disclosure and food security could help women adhere to ART.

We found wide variation in prevalence of virologic non-suppression between clinics; however, there were no discernable differences in facility characteristics. Women attending clinics with a high prevalence of virologic non-suppression had significantly lower ART adherence
behavior skills scores and higher prevalence of at least mild depression than women at the other clinics, which suggests participant rather than facility factors explained differences in virologic non-suppression prevalence between clinics. Because behavior scores varied by clinic, clinic-adjusted analyses may have adjusted away these associations. Thus, understanding both overall and site-adjusted cofactors is important in our study.

Conclusions

In summary, we found that virologic non-suppression among pregnant WLWH on ART was more frequent among women who had not disclosed their HIV status, were food insecure, or had lower adherence behavioral skills. Addressing these factors may improve viral suppression among pregnant women. Peer navigators, mentor mothers, or interventions to increase male partner involvement may be beneficial [36]. Our resistance data suggest that non-suppression was often due to resistance. While prevalence of resistance will decrease as PMTCT programs move to dolutegravir use, women on NNRTI regimens would benefit from resistance testing. Assessing behavioral skills with the Lifewindows IMB instrument may be useful to prioritize women for adherence interventions and to monitor intervention effects in PMTCT programs.

Supporting information

S1 Fig. Schematic representation of HIV drug resistance in study women with unsuppressed plasma viral load. Of the 470 pregnant women living with HIV on ART for ≥4 months, 57 (12.1%) had unsuppressed plasma viral load (HIV viral load ≥1000) at enrollment. Of these, blood samples were available for 54 women, and of those 35 women (64.8%) had detectable drug resistance mutations mainly to NNRTI antiretrovirals. The majority of the women with detectable HIV drug resistance mutations, as assessed by >10% level using oligonucleotide assay (OLA) and consensus sequencing, were on 1st line NNRTI-based ART, except for three women on Protease-inhibitor based ART had NNRTI drug resistance mutation. NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; ART (antiretroviral) regimen: TDF = tenofovir; 3TC = lamivudine; ZDV = Zidovudine; EFV = efavirenz; NVP = nevirapine; LPV/r = ritonavir-boosted lopinavir; **TAMs = Thymidine analogue mutations (*1 TAM (n = 1), **2 TAMs (n = 2)).

(S1 Table. Differences in facility characteristics.)

(S2 Table. Differences in individual-level characteristics by site.)

Acknowledgments

The authors thank everyone who has been involved in this study, particularly the study participants who contributed the data used in this study.

Author Contributions

Conceptualization: Bhavna H. Chohan, Jennifer A. Unger, Alison L. Drake, John Kinuthia, Grace John-Stewart.

Data curation: Bhavna H. Chohan, Keshet Ronen, Lusi Osborn, Grace John-Stewart.

Formal analysis: Bhavna H. Chohan, Keshet Ronen, Grace John-Stewart.
Funding acquisition: Jennifer A. Unger, Alison L. Drake, John Kinuthia, Grace John-Stewart.

Investigation: Bhavna H. Chohan, Brian Khasimwa, Daniel Matemo, Jennifer A. Unger, Alison L. Drake, Grace John-Stewart.

Methodology: Bhavna H. Chohan, Ingrid A. Beck, Lisa M. Frenkel, Grace John-Stewart.

Project administration: Daniel Matemo, Alison L. Drake, John Kinuthia.

Resources: Brian Khasimwa, John Kinuthia, Grace John-Stewart.

Software: Keshet Ronen, Lusi Osborn, John Kinuthia, Grace John-Stewart.

Supervision: Keshet Ronen, Daniel Matemo, Jennifer A. Unger, Grace John-Stewart.

Validation: Keshet Ronen, Grace John-Stewart.

Visualization: Jennifer A. Unger, Alison L. Drake, John Kinuthia, Grace John-Stewart.

Writing – original draft: Bhavna H. Chohan, Keshet Ronen.

Writing – review & editing: Bhavna H. Chohan, Keshet Ronen, Grace John-Stewart.

References

1. Global AIDS Update 2018. MILES TO GO. Closing Gaps, Breaking Barriers, Righting injustices. UNAIDS. https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf

2. Matthews LT, Orrell C, Bwana MB, Tsai AC, Psaros C, Asiimwe S, et al. Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12-month cohort study in urban South Africa and rural Uganda. J Int AIDS Soc. 2020; 23: 1–11. https://doi.org/10.1002/jia2.25586 PMID: 32820622

3. Haas AD, Muskwa MT, Egger M, Tenthani L, Twyca H, Jahn A, et al. Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi’s Option B+ Program. Clin Infect Dis. 2016; 63: 1227–1235. https://doi.org/10.1093/cid/ciw500 PMID: 27461920

4. Machnowska P, Hauser A, Meixenberger K, Altmann B, Bannert N, Rempis E, et al. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT. PLoS One. 2017; 12: 1–15. https://doi.org/10.1371/journal.pone.0178297 PMID: 28562612

5. Hosseinipour M, Nelson JAE, Trance C, Rutstein SE, Kasende F, Kayovo Y, et al. Viral suppression and HIV drug resistance at 6 months among women in Malawi’s option B+ program: Results from the PURE Malawi study. J Acquir Immune Defic Syndr. 2017; 75: S149–S155. https://doi.org/10.1097/QAI.0000000000001368 PMID: 28498184

6. Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McCleren H, Denti P, et al. Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2016; 71: 31–37. https://doi.org/10.1097/QAI.0000000000000811 PMID: 26334739

7. Ngarina M, Kilewo C, Karlsson K, Aboud S, Karlsson A, Marrone G, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis. 2015; 15: 1–10. https://doi.org/10.1186/s12879-014-0722-x PMID: 25567701

8. Abuogi LL, Humphrey JM, Mpody C, Yotebieng M, Murmane PM, Clouse K, et al. Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs. J Virus Erad. 2016; 4: 33–39. PMID: 30515312

9. Adeniyi OV, Ajayi AI, Goon D T, Owolabi EO, Eboh A, Lambert J. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. BMC Infect Dis. 2018; 18: 1–11. https://doi.org/10.1186/s12879-017-2892-9 PMID: 29291173

10. Psaros C, Smij JA, Moser N, Soc B, Bennett K, Coleman J, et al. PMTCT Adherence in Pregnant South African Women: The Role of Depression, Social Support, Stigma, and Structural Barriers to Care. Ann behav med. 2020; 54: 626–636. https://doi.org/10.1093/abm/kaaai05 PMID: 32128556

11. Nachega JB, Uthman OA, Anderson J, Ho Y, Stringer JSA, McIntyre JA, et al. Adherence to Antiretroviral Therapy During and After Pregnancy in Low-, Middle and High Income Countries: A Systematic Review and Meta-Analysis. AIDS. 2012; 26: 2039–2052. https://doi.org/10.1097/QAD.0b013e328359970f PMID: 22951634
12. Onono M, Odwar T, Abuogi L, Owuor K, Helova A, Bukusi E, et al. Effects of Depression, Stigma and Intimate Partner Violence on Postpartum Women’s Adherence and Engagement in HIV Care in Kenya. AIDS Behav. 2019; 24: 1807–1815. https://doi.org/10.1007/s10461-019-02750-y PMID: 31813076

13. Alibibula W, Cox J, Hamelin A, McInden T, Klein MB, Brassard P. Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. AIDS Behav. 2017; 21: 754–765. https://doi.org/10.1007/s10461-016-1605-5 PMID: 27837425

14. Weiser SD, Palar K, Frongillo EA, Tsai AC, DePee S, et al. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. AIDS. 2014; 28: 115–120. https://doi.org/10.1097/01.aids.0000433238.93986.35 PMID: 2399234

15. Nagata JM, Magarenge R, Young SL, Oguta J, Weiser SA, Cohen CR. Social determinants, lived experiences, and consequences of household food insecurity among persons living with HIV/AIDS on the shore of Lake Victoria, Kenya. AIDS Care. 2012; 24: 728–736. https://doi.org/10.1080/09540121.2011.630358 PMID: 22150119

16. Murnane PM, Miller JD, Tuthill EL, Collins SM, Neilands TB, Onono M, et al. Perinatal Food Insecurity and Postpartum Psychosocial Stress are Positively Associated Among Kenyan Women of Mixed HIV Status. AIDS Behav. 2020; 24: 1632–1642. https://doi.org/10.1007/s10461-019-02676-5 PMID: 31538283

17. Garcia J, Horni-fiedler A, Mazur RE, Marquis G, Sellen D, Larney A, et al. Persistent household food insecurity, HIV, and maternal stress in Peri-Urban Ghana. BMC Public Health. 2013; 13: 1–9. https://doi.org/10.1186/1471-2458-13-1 PMID: 23280303

18. Drake AL, Unger JA, Ronen K, Matemo D, Perrier T, DeRenzis B, et al. Evaluation of mHealth strategies to optimize adherence and efficacy of Option B+ prevention of mother-to-child HIV transmission: Rationale, design and methods of a 3-armed randomized controlled trial. Contemp Clin Trials. Elsevier Inc.; 2017: 57: 44–50. https://doi.org/10.1016/j.cct.2017.03.007 PMID: 28315480

19. The LifeWindows Project Team. LifeWindows Inf Motiv Behav Ski ART Adherence Quest (LW-IMB-AAQ) 2006. Available: Center for Health, Intervention, and Prevention. University of Connecticut.

20. Sherbourne CD, Stewart AL. THE MOS SOCIAL SUPPORT SURVEY. Soc Sci Med. 1991; 32: 705–714. https://doi.org/10.1016/0277-9536(91)90150-b PMID: 2035047

21. Mcfarlane J, Hughes RB, Nosek MA, Groff JY, Sivated N, Mullon PD. Abuse Assessment Screen-Disability (AAS-D): Measuring frequency, type, and perpetrator of abuse toward women with physical disabilities. J Womens Heal Gender-Based Med. 2001; 10: 861–866. https://doi.org/10.1089/jwh.2001.10.861 PMID: 11747680

22. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med. 2001; 16: 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x PMID: 11556941

23. Rao D, Choi SW, Victors D, Bode R, Peterman A, Cell D. Measuring Stigma Across Neurological Conditions: The Development of the Stigma Scale for Chronic Illness (SSCI). Qual Life Res. 2009; 18: 585–595. https://doi.org/10.1007/s11136-009-9475-1 PMID: 19396572

24. Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for Measurement of Food Access: Indicator Guide. USAID. Food Nutr Tech Assist. 2007: Version 3.

25. Beke IA, Deng W, Payant R, Hall R, Bumgarner RE, Mullins JI, et al. Validation of an Oligonucleotide Ligation Assay for Quantification of Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by Use of Massively Parallel Sequencing. 2014; 52: 2320–2327. https://doi.org/10.1128/JCM.00306-14 PMID: 24740080

26. StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.

27. Chetty T, Newell ML, Thorne C, Coutoudis A. Viriaemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010–2015. Trop Med Int Heal. 2018; 23: 79–91. https://doi.org/10.1111/tmi.13001 PMID: 2921445

28. Chan M, Munene JM, Emery S, Kanthula R, Chohan V, Frenkel LM, et al. Correlates of HIV detection among breastfeeding postpartum Kenyan women eligible under Option B+. PLoS One. 2019; 14(5): 1–13. Available: https://doi.org/10.1371/journal.pone.0216252 PMID: 31150396

29. Mancinelli S, Galluzzo CM, Andreotti M, Liotta G, Jere H, Sagoon J, et al. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Res Hum Retroviruses. 2016; 32: 737–742. https://doi.org/10.1089/AID.2015.0366 PMID: 27067142

30. Atanga PN, Ndetan HT, Fon PN, Meriki HD, Mufith TP, Achidi EA. Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B+. BMC Pregnancy Childbirth. BMC
31. KENYA AIDS RESPONSE PROGRESS REPORT 2018, Ministry of Health, National AIDS Control Council, Kenya. http://nacc.or.ke/wp-content/uploads/2018/11/KARPR-Report_2018.pdf

32. Lyerly AD. Dolutegravir: advancing ethical research in pregnancy. Lancet. Elsevier Ltd; 2019; 394: 1972–1974. https://doi.org/10.1016/S0140-6736(19)32638-8 PMID: 31789207

33. Yang L, Li Q, Zhou L, Chen S. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Int J Antimicrob Agents. 2019; 54: 547–555. https://doi.org/10.1016/j.ijantimicag.2019.08.008 PMID: 31398480

34. Aunon FM, Okada MSE, Wanje G, Masese MPHL, Odeny TA, Kinuthia J, et al. Iterative Development of an mHealth Intervention to Support Antiretroviral Therapy Initiation and Adherence Among Female Sex Workers in Mombasa, Kenya. J Assoc Nurses AIDS Care. 2020; 31: 145–156. https://doi.org/10.1097/JNC.000000000000157 PMID: 31868829

35. Peng Z, Yu Y, Wei W, Hou Y, Sun Z, Wang Y, et al. Reliability and Validity of the LifeWindows Information–Motivation–Behavioral Skills Antiretroviral Therapy Adherence Questionnaire Among HIV + Patients in Shanghai. Patient Prefer Adherence. 2020; 14: 507–515. https://doi.org/10.2147/PPA.S234041 PMID: 32184577

36. Koss C., Natureeba P, Kwarisiima D, Ogena M, Clark T., Olwoc P, et al. Viral suppression and retention in care up to 5 years after initiation of lifelong art during pregnancy (option B+) in rural Uganda. J Acquir Immune Defic Syndr. 2017; 74: 279–284. https://doi.org/10.1097/QAI.0000000000001228 PMID: 27828678

37. Leddy AM, Sheira LA, Tamraz B, Sykes C, Kashuba ADM, Wilson TE, et al. Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2020; 71(6): 1517–1523. https://doi.org/10.1093/cid/ciz1007 PMID: 31608363